Evidence map›Paper›PMID 31098725›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2019

Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease.

Anna Delamarre, François Tison, Qin Li, Monique Galitzky, Olivier Rascol, Erwan Bezard, Wassilios G Meissner

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Anna DelamarreService de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, 33000, Bordeaux, France.
François TisonService de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, 33000, Bordeaux, France.
Qin LiInstitute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.
Monique GalitzkyCIC Toulouse, Toulouse, France.
Olivier RascolCIC Toulouse, Toulouse, France.
Erwan BezardService de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, 33000, Bordeaux, France.
Wassilios G MeissnerService de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, 33000, Bordeaux, France. wassilios.meissner@chu-bordeaux.fr.ORCID 0000-0003-2172-7527
Centre National de la Recherche Scientifique · FRCentre d’Investigation Clinique 1436 · FRChinese Academy of Medical Sciences & Peking Union Medical College · CNInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We tested in a translational approach the usefulness of plasma creatine kinase (CK) as an objective biomarker for levodopa-induced dyskinesia (LID). Plasma CK levels were measured in five dyskinetic parkinsonian non-human primates (NHP) and in ten PD patients with LID who participated in a treatment trial with simvastatin. Plasma CK levels were increased in dyskinetic NHP and correlated with LID severity while they were not affected by LID severity in PD patients.

Indexed as

AgedAnimalsAntiparkinson AgentsBiomarkersCreatine KinaseDisease Models, AnimalDyskinesia, Drug-InducedHumansLevodopaMacacaMiddle AgedParkinson DiseaseRandomized Controlled Trials as TopicSeverity of Illness IndexAntiparkinson AgentsBiomarkersCreatine KinaseLevodopaBiomarkerCreatine kinaseLevodopa-induced dyskinesiaParkinson’s disease

Identifiers

PMID31098725
OpenAlexW2946656875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.